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Background: Globally, diarrhoea is the second leading cause of morbidity and mortality, responsible for the annual
loss of about 10% of the total global childhood disease burden. In Tanzania, Rotavirus infection is the major cause
of severe diarrhoea and diarrhoeal mortality in children under five years. Immunisation can reduce the burden, and
Tanzania added rotavirus vaccine to its national immunisation programme in January 2013. This study explores the
cost effectiveness of introducing rotavirus vaccine within the Tanzania Expanded Programme on Immunisation (EPI).
Methods: We quantified all health system implementation costs, including programme costs, to calculate the cost
effectiveness of adding rotavirus immunisation to EPI and the existing provision of diarrhoea treatment (oral rehydration
salts and intravenous fluids) to children. We used ingredients and step down costing methods. Cost and coverage data
were collected in 2012 at one urban and one rural district hospital and a health centre in Tanzania. We used Disability
Adjusted Life Years (DALYs) as the outcome measure and estimated incremental costs and health outcomes using a
Markov transition model with weekly cycles up to a five-year time horizon.
Results: The average unit cost per vaccine dose at 93% coverage is US$ 8.4, with marked difference between the urban
facility US$ 5.2; and the rural facility US$ 9.8. RV1 vaccine added to current diarrhoea treatment is highly cost effective
compared to diarrhoea treatment given alone, with incremental cost effectiveness ratio of US$ 112 per DALY averted,
varying from US$ 80–218 in sensitivity analysis. The intervention approaches a 100% probability of being cost effective at
a much lower level of willingness-to-pay than the US$609 per capita Tanzania gross domestic product (GDP).
Conclusions: The combination of rotavirus immunisation with diarrhoea treatment is likely to be cost effective when
willingness to pay for health is higher than USD 112 per DALY. Universal coverage of the vaccine will accelerate progress
towards achievement of the child health Millennium Development Goals.
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Diarrhoea is the second leading cause of morbidity and
mortality globally among children below five years of
age and is responsible for 23 million Disability Adjusted
Life Years (DALYs) annually, about 10% of the total glo-
bal childhood disease burden [1]. The global burden of
diarrhoea is highest among children in low-income
countries, with countries in sub-Saharan Africa account-
ing for more than 50 per cent of cases worldwide [1]. In
Tanzania, about fourteen per cent of all deaths in* Correspondence: ruhagogm@gmail.com
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unless otherwise stated.children younger than five years is due to diarrhoea,
making it liable for five per cent of the total national
DALYs [1,2]. About 70 per cent of the burden occurs be-
fore the first birthday. Tanzanian children under the age
of five, are estimated to have 3.5 episodes of diarrhoea
per year, reaching a peak frequency between 6–12
months of 4.72 episodes per year [3]. Rotavirus is the
single most important cause of diarrhoea: estimated to
represent about 40 per cent of all diarrhoea related mor-
bidity and mortality in children globally [4]. Similar diar-
rhoea causality has been observed in a multi-country
study, which included Tanzania, where 34 percent of all
diarrhoea episodes were due to rotavirus [5].
The introduction of integrated management of childhood
illness (IMCI) more than two decades ago strengthened thel. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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rehydration solution (ORS) as a main intervention for
diarrhoea treatment, recommended by World Health
Organization (WHO) and United Nations Children’s
Fund (UNICEF) [7]. Treatment of diarrhoea with ORS
has shown marked effectiveness in preventing dehydra-
tion and reducing diarrhoea related mortality [8]. To
achieve optimal effectiveness, diarrhoea treatment
adopting the principles of IMCI requires large coverage
and community participation. However, the recent em-
phasis on vertical programmes, targeting specific dis-
eases such as Malaria, TB and HIV/AIDS, has led to
reduced funding for IMCI and has weakened the man-
agement and control of diarrhoea [9].
WHO recommends including rotavirus vaccine into
national immunization programmes [10]. Tanzania did
this under the support of the GAVI Alliance in January
2013 [11]. Two rotavirus vaccines are currently available
for Tanzania. Rotarix®, by GlaxoSmithKline, is a single
strain, live attenuated human rotavirus vaccine (RV1)
administered orally in two doses. RotaTeq®, by Merck &
Co Inc., is a live, human-bovine reassortant pentavalent
rotavirus vaccine (RV5), administered orally in three
doses. A third vaccine LLR, Lanzhou Institute Biomed-
ical Products is a three dose vaccine currently licensed
for use in China only, while a fourth Indian vaccine
(ROTAVAC), has shown promising results but is not yet
available for scale up [12]. WHO recommends that in-
fants are vaccinated between six and fifteen weeks, and
that the last dose is not given later than 32 weeks of age
[13,14]. The introduction of RV1 in Tanzania offered a
unique opportunity to quantify all health system imple-
mentation costs, including programme costs, during
planning, piloting and scale-up of the new programme.
The aim of this study was to collect primary cost data
from the perspective of the health care provider and to
compare the cost-effectiveness of the RV1 rotavirus vac-
cine to existing treatment strategies for diarrhoea in
children.
Methods
Study setting and perspective
The study was a cost effectiveness analysis from the per-
spective of health service providers in Tanzania. We
adopted a health provider perspective because this infor-
mation would be important for national health decision
makers, and because a wider societal perspective is
much more data intensive and would require data that
are not easily available in this setting. We compared the
current treatment of diarrhoea (using oral rehydration
salt (ORS) and intravenous (IV) fluid), with the addition
of rotavirus vaccination to the current diarrhoea treat-
ment and with the provision of rotavirus vaccine (RV1)
alone. In addition we included a hypothetical alternativeof providing no treatment to reflect further on what the
outcome might be if the interventions were not imple-
mented [15]. The pentavalent rotavirus vaccine (RV5)
strategy was not included in the model analysis due to
lack of cost data in Tanzania.Description of interventions
Treatment of diarrhoea in children with ORS and IV
fluids in Tanzania follows a three-step plan (A-C) de-
pending on diarrhoea severity, which is determined by
dehydration status. Plan A should be followed for cases
of mild diarrhoea, plan B for moderate and plan C for
severe diarrhoea [16]. The single strain live attenuated
human rotavirus vaccine (RV1) is administered to in-
fants orally in two doses, the first dose at six weeks and
the second at ten weeks [14].Costs
We collected primary cost data for diarrhoea management
and additional costs of introducing RV1 to the national
immunisation programme in two districts, purposely sam-
pled to include a rural district (Kisarawe) and an urban
district (Ilala). Costing was done from a health provider
perspective. In each district we collected data from one
hospital (Amana hospital for Ilala and Kisarawe hospital for
Kisarawe district) and one health centre (Chanika Health
Centre in Ilala and Masaki Health Centre in Kisarawe) for
the one-year period July 2011 to June 2012. We collected
the cost data before the introduction of rotavirus vaccine,
but the preparation for the rollout was at an advanced
stage, including plans for the procurement and distribution
of vaccines, training of health personnel and the prepar-
ation for storage facilities. In case the available information
on resource use was not sufficient we used information on
other vaccines under the expanded programme on immun-
isation (EPI). We used a modified WHO and Joint United
Nations Programme on HIV and AIDS (UNAIDS) costing
tool, to identify all resource use [15,17].Resource identification
We categorised health facility departments into three
costing centres and applied the ingredient approach as
proposed by WHO-CHOICE to identify resource use in
each of the cost centres [15]. First, we identified all re-
sources used in centres that directly provide services for
child immunisation, and outpatient and inpatient depart-
ments that provide diarrhoea treatment to children. Sec-
ond, we identified resources used in indirect care cost
centres that provided services but not direct medical
care (ancillary services). Thirdly, we included other sup-
port service cost centres such as general administrative
and warehouse costs.
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Resource use was categorised into recurrent and capital
goods. We classified capital items as those with useful
life years above one year or costing above Tsh100000
(about 62 US$). Resource use was measured through re-
view of available inventories such as ledgers, order
books, and records of medical supplies used. All records
were anonymous, only specifying resources used in
treating diarrhoea or providing rotavirus vaccine. We
employed a step down costing approach to allocate re-
sources between cost centres [18]. The proportion of the
number of workers at each cost centre as a percentage
of total workers at the health facility was used to allocate
shared resources to the cost centres. The number of
diarrhoea patients among all inpatient and outpatient at-
tendees, and the number of rotavirus doses as a percent-
age of all vaccine doses were used as a proxy to obtain
specific resource use by each intervention.
To value all identified resources for rotavirus vaccin-
ation and diarrhoea management, we used the Tanzania
Medical Stores price catalogue to assign costs for medical
equipment and drugs [19]. The cost of non-medical equip-
ment was obtained from 2011/2012 tender prices for the
Government Procurement Services Agency (GPSA) [20].
Building rents were estimated as per Tanzania National
Housing Corporation (NHC) rental charges obtained
through interview with key personnel at NHC. All cost
data were collected in Tanzania shillings (TSH) and con-
verted to US dollars using the Bank of Tanzania Interbank
average annual exchange rates for 2011 and 2012 [21].
The capital costs were annuitized using Bank of
Tanzania average interest rates for 2011/ 2012 at 9.6 per
cent [21], and we adopted useful life years from WHO
country estimates [22]. All data were analysed using
Microsoft Excel (2010).Unit cost
To obtain the unit cost per immunized child, we divided
the total cost by the total estimated number of children to
be vaccinated with the RV1 vaccine, obtained from the
current coverage levels of the existing child immunisation
package (DPT- HB) from each of the study facilities. Out-
patient (OPD) unit costs were obtained by dividing the
total OPD cost (capital and recurrent cost) by the annual
number of children with moderate diarrhoea visiting the
OPD. Inpatient (IPD) unit costs were derived by dividing
the total IPD cost (capital and recurrent cost) by the total
number of IPD bed days specific to children admitted with
severe diarrhoea. To obtain the total unit cost, the urban/
rural costs were weighted using the proportion of popula-
tion attending at each health facility, and the proportion of
the population in each district. We assumed the constant
returns to scale, i.e. the same unit prices for administrationand disease management apply both with and without the
intervention.
Effectiveness
Through a systematic search we identified the most re-
cently updated systematic reviews and meta-analyses of
the effectiveness of the RV1 vaccine [14]. Only one mul-
ticentre double blinded, randomized placebo-controlled
study conducted in South Africa and Malawi [23], re-
ported rota vaccine efficacy on all-cause diarrhoea for
countries with high diarrhoea mortality rates. The data
analysis was conducted according to the protocol. The
efficacy from this trial is used in our study. The effect-
iveness of diarrhoea treatment using ORS was retrieved
from a systematic review by Munos et al. [24]. The ef-
fectiveness of IV fluids against severe diarrhoea were
obtained from a Cochrane systematic review by Hartling
et al. [25]. In our model we used vaccine efficacy against
all-cause severe diarrhoea to reflect the real Tanzanian
clinical settings whereby routine management of diar-
rhoea is based on clinical assessment criteria. Key input
parameters are listed in Table 1.
Markov model overview
We constructed an individual Markov state-transition
model (Figure 1) with weekly cycles with TreeAge Pro
2013 software (Williamstown, MA, USA). A five-year
time horizon was adopted to reflect the fact that diar-
rhoea from rotavirus infection is primarily a health prob-
lem during the first five years of life [3,5,10].
For each weekly cycle in the model, children can be in
one of four possible health states; well/asymptomatic in-
fection (1), moderate diarrhoea (2), severe diarrhoea (3)
and dead (4). Children in the well/asymptomatic state
are exposed to diarrhoea infections. For each cycle, the
child may remain well, contract moderate diarrhoea or
die from other causes (background mortality). In the
moderate state, children may recover from diarrhoea in-
fection, continue with recurrent moderate diarrhoea,
progress to severe diarrhoea or die from other causes.
Individuals progressing to severe diarrhoea may recover,
continue with recurrent moderate diarrhoea or die from ei-
ther diarrhoea or other causes. The model assumptions
were based on the diarrhoea classification by severity de-
scribed in the Tanzania national treatment guideline [16].
Transition probabilities
The movement between health states (as described
above) is modelled on the basis of transition probabil-
ities and the effectiveness values of the diarrhoea treat-
ment options in the model. The probabilities were
obtained from the literature. The probabilities of acquir-
ing moderate diarrhoea infections are based on age
specific incidence for Tanzania (Table 1) [3]. Yearly
Table 1 Key input parameters for cost-effectiveness base case and sensitivity analyses
Parameter Base case Range Distribution Source
Cost (2012 US$)
Cost per fully immunised child for rota vaccine (RV1) at 93% coverage (cRotaVac)** 16.99 ±25% Gamma Table 2
Cost per OPD visit for diarrhoea treatment (cModD) 3.84 ±25% Gamma Table 3
Cost of in-patient diarrhoea treatment per bed day (cSevD) 8.90 ±25% Gamma Table 4
Cost discounting rate (cDR) 0.03 0.00 – 0.06 N/A [15]
Disability weights
Disability weight moderate Diarrhoea (uModD) 0.202 0.133 - 0.299 Beta [32]
Disability weight severe Diarrhoea (USevD) 0.281 0.184 - 0.399 Beta [32]
Outcome discounting rate (oDR) 0.030 0.000 – 0.060 N/A [15]
Effectiveness (Relative Risk ratio)
Effectiveness of RotaVaccine on all cause diarrhoea (effRotaVac) 0.698 0.570 - 0.850 Log-normal [23]
Effectiveness of IMCI on moderate diarrhoea (effImci_OPD) 0.590 0.430 - 0.680 Log-normal [24]
Effectiveness of IMCI on severe diarrhoea (effImci_IPD) 0.570 0.420 - 0.660 Log-normal [25]
Transition Probabilities (weekly)
Probability of progressing from well to moderate diarrhoea (tpModD) 0.116 0.072 - 0.167 Beta [3]
Probability of progressing from moderate to severe diarrhoea (tpSevD) 0.048 0.035 - 0.056 Beta [27]
Probability of recurrent moderate diarrhoea (tpRecModD) 0.005 0.004 – 0.006 Beta [28]
Probability of recurrent severe diarrhoea (tpRecSevD) 0.0038 0.003 – 0.0045 Beta [28]
Mortality
Probability of dying from diarrhoea (Case fatality rate (CFR) <5 yrs (%)) 0.019 0.0119 -0.0265 Normal [27]
(PDeath_NoInt)
General
Average number of bed days spent in hospital 4 2 - 6 N/A Primary data
Diarrhoea treatment coverage rates 41% 44%-68% N/A [30]
Vaccine coverage rates ( reference to DPT-HB-Hib coverage) 93% 85% – 95% N/A [30]
Healthy life expectancy at birth 52 49,4 - 53,1 N/A [32]
**In the model the vaccination cost are assigned once as transition cost to vaccinated child on first and second dose i.e. only during a monthly cycle
corresponding to vaccination.
Figure 1 Markov model showing the health states of diarrhoeal disease, including “well/asymptomatic”, “moderate diarrhoea”, “severe diarrhoea”
and “dead”, which is an absorbing state.
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diarrhoea infections using the formula p = 1- exp(−rt)
where p = probability, r = rate, t = time period (weekly)
[26]. The transition probability of progressing from
moderate to severe diarrhoea is based on a systematic
review by Walker et al. [27], while the probabilities of re-
current moderate and severe diarrhoea were taken from
Lamberti et al. [28] (Table 1).
To estimate the likelihood of mortality from diarrhoea
infection, case fatality rates (CFR) for diarrhoea were re-
trieved through a literature search [27]. We used a
Tanzanian life table for the year 2011 to estimate the risk
of all-cause mortality, which was adjusted for diarrhoea
mortality to calculate background mortality rates [29].
We assumed a reasonable target coverage of rotavirus
vaccine to be equal to DPT-HB vaccine coverage (93%)
[30]. We applied a dropout rate of 5% for the second
dose, on the basis of the 2010 Tanzania Demographic
and Health Survey (TDHS) [30].
Health outcomes
We estimated health outcomes using disability-adjusted
life years (DALYs). DALYs were calculated in the Markov
model by combining years lived with disability (YLD)
and years of life lost (YLL) for each weekly cycle. DALYs
averted were calculated for each cycle and accumulated
over the model time horizon. This was repeated for each
diarrhoea management strategy [31]. DALYs averted
were calculated as the difference between the treatment
strategies. To obtain YLD, we used recently updated dis-
ability weights of 0.202 and 0.281 for moderate and severe
diarrhoea [32]. For children in a well state a disability
weight of 0 was applied, assuming all individuals in this
state are either healthy or with asymptomatic diarrhoea
[32]. We did not incorporate age weighting since this is not
recommended in the most recent DALY guidelines [33].
To compute YLL, a disease weight of 1 reflecting the
worst state (i.e., death) and a healthy life expectancy at
birth for Tanzania, 52 years, was used [34]. All individ-
uals in the state of death were assigned a weight of 1. At
the final cycle all cohorts ending up in the state of well-
ness were assigned a final reward equal to the healthy
life expectancy at two years [31].
Cost effectiveness analysis
We used the hypothetical no intervention as a baseline
and compared it to the modelled incremental cost effect-
iveness ratios (ICERs) of implementing the current stand-
ard of care for diarrhoea treatment in children, adding the
RV1 vaccine to the current diarrhoea treatment, and RV1
vaccine given alone. The base case ICER was computed by
dividing the incremental cost to incremental DALYs
averted in each of the study interventions. Costs and ef-
fectiveness were discounted at an annual rate of 3%recommended by WHO for low income countries [15].
Most economic evaluation guidelines recommend dis-
counting of both cost and effects, which is also reflected
in the applied literature [18,35,36].
Sensitivity analyses
We performed one-way sensitivity analyses to evaluate
the impact of single assumptions on costs and outcomes.
As upper and lower variable ranges, we used upper and
lower 95% confidence limits, respectively, wherever re-
ported in the literature. When confidence intervals were
not reported and for the primary cost data we used a
range of +/− 25% (Table 1). This reflects a reasonable
range of variation in cost and is commonly used in cost
effectiveness studies [37-39].
We used probabilistic sensitivity analysis to assess the
overall robustness of the results. We did this by running
the model with distributions for each parameter rather
than point estimates. We computed distributions for the
parameters using base case values as means, and stand-
ard errors calculated from uncertainty ranges (Table 1).
For disability weights and transition probabilities, beta
distributions were used since this restricts values to the
range between 0 and 1. Gamma distributions were used
for costs to avoid negative values [26], while, log-normal
distributions were assumed for relative risks.
Monte Carlo simulation was used to draw 10,000 ran-
dom samples from the distributions that were combined
into cost-effectiveness pairs. The cost-effectiveness pairs
were used to estimate the probability that each interven-
tion is cost effective for a range of willingness to pay to
avert DALYs. The results of the probabilistic sensitivity
analysis are presented as a cost-effectiveness scatter plot
and a cost-effectiveness acceptability curves.
Research ethics
Ethical clearance was obtained from Medical Research
Coordinating Committee of the National Institute for
Medical Research, Tanzania. All data used in the study
were anonymous; only record books without any patient
identity were used. The funding agency had no influence
on the study design or results.
Results
Costs
The total weighted average cost of rolling out RV1 vac-
cine at 93% coverage is US$ 8.4 per vaccine dose. The
weighted unit cost per vaccine dose is US$ 5.2 in urban
health facility and US$ 9.8 in rural facilities (Table 2).
Recurrent costs account for 89% in urban and 87% in
rural facilities. In urban facilities, 60% and, in rural facil-
ities , 39% of the total cost is used for purchase and dis-
tribution of vaccines.
Table 2 Average cost for providing rotavirus vaccine services, 2012 US$
Cost category Urban Rural
Hospital % Health
Centre
% Average % Hospital % Health
Centre
% Average %
Capital Cost, N (%)
Buildings 582 2.6 517 5.3 550 3.5 504 8.3 265 4.8 384 6.6
Equipment 234 1.1 210 2.2 222 1.4 163 2.7 147 2.7 155 2.7
Vehicles 140 0.6 140 1.4 140 0.9 36 0.6 33 0.6 35 0.6
Training on IMCI 281 1.3 249 2.6 265 1.7 236 3.9 189 3.4 213 3.7
Total capital costs 1237 5.6 1116 11.5 1177 7.4 939 15.4 634 11.5 787 13.5
Recurrent Cost, N (%)
Personnel 7030 32.0 1188 12.3 4109 26.0 1997 32.8 1649 29.9 1823 31.4
Vaccine 12498 56.9 6477 67.0 9487 59.9 2197 36.0 2338 42.3 2268 39.0
Supplies 175 0.8 150 1.6 163 1.0 83 1.4 76 1.4 79 1.4
Vehicle operation and maintenance 56 0.3 56 0.6 56 0.4 52 0.9 32 0.6 42 0.7
Building operation and maintenance 468 2.1 18 0.2 243 1.5 59 1.0 15 0.3 37 0.6
Community sensitisation and Monitoring 516 2.3 671 6.9 594 3.8 658 10.8 658 11.9 658 11.3
Outreach - - - 112 1.8 123 2.2 117 2.0
Total recurrent costs 20743 94.4 8560 88.5 14652 92.6 5158 84.6 4891 88.5 5024 86.5
Grand Total 21980 9676 15829 6097 5525 5811
Unit Cost
Number of doses administered 4041 2094 711 477
Cost per dose at 93% 5.4 4.6 5.0 8.6 11.6 10.1
% proportion of hospital/health centre
administered doses
66 % 34 % 60 % 40%
Weighted unit cost per dose 3.6 1.6 5.2 5.1 4.7 9.8
% proportion of urban\rural population 29 % 71%
Urban/rural weighted cost per dose 1.5 6.9
Weighted average cost (Urban/rural) per dose 8.4
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management in urban and rural health facilities in more
detail. The cost of managing a case of moderate diar-
rhoea is US$ 2.9 per visit (Table 3) in urban facilities,
and US$ 4.2 per visit in rural facilities. Severe diarrhoea
management costs US$ 7.6 and US$ 9.4 per bed day in
urban and rural health facilities, respectively. Personnel
remuneration is the major expenditure, consuming 62%
in urban and 39% in rural facilities of the total cost for
treating moderate diarrhoea. There is a similar trend for
severe diarrhoea with personnel remuneration represent-
ing 64% and 42% of total expenditure for urban and
rural facilities, respectively.
Cost-effectiveness
At baseline, providing only rotavirus immunisation is
the least effective of the alternatives, with 1.4 DALYs
averted per child, while diarrhoea management alone
and vaccine plus diarrhoea treatment in combinations
avert 2.0 and 2.5 DALYs per child respectively.The vaccine alone is also the cheapest of the alternatives
with a cost estimate of US$ 59 per child, while the cost of
diarrhoea treatment is US$ 112 and the vaccine and treat-
ment in combination is US$ 167 per child. There is no
dominance, and the incremental cost-effectiveness ratios
(ICERs) are US$ 43 and 112 per DALY averted when mov-
ing between the three alternatives (Table 5). Rotavirus vac-
cine in combination with diarrhoea treatment using ORS
and IV fluids is therefore the most cost-effective option
compared to the vaccine or diarrhoea treatment alone
(Table 5), given that the willingness to pay is at least US$
112 per DALY.
One-way sensitivity analysis
The one-way sensitivity analysis indicates that the vac-
cine efficacy of diarrhoea is the most influential param-
eter in the base case analysis (Figure 2). Evaluating the
model at the lower limit of the effectiveness of rotavirus
vaccine on all cause diarrhoea (0.57), the ICER improved
significantly from US$ 112 to US$ 80 per DALY averted,
Table 3 Average outpatient cost diarrhoea treatment per visit, by location and level of service, 2012 US$
Cost category Urban Rural
Hospital % Health
Centre
% Average % Hospital % Health
Centre
% Average %
Capital Cost, N (%)
Buildings 4016 12.3 84 12.2 2050 12.3 61 4.3 160 17.3 111 9.4
Equipment 362 1.1 5 0.7 184 1.1 9 0.6 16 1.7 12 1.1
Vehicles 446 1.4 27 3.9 237 1.4 22 1.5 0 0.0 11 0.9
Training on diarrhoea management 1328 4.1 269 39.0 799 4.8 802 56.6 72 7.8 437 37.3
Total capital costs 6152 18.9 385 55.6 3268 19.6 893 63.0 248 26.8 571 48.7
Recurrent Cost, N (%)
Personnel 20371 62.4 204 29.5 10288 61.8 299 21.1 622 67.1 460 39.3
Drugs and Medical supplies 3879 11.9 63 9.1 1971 11.8 58 19.1 47 5.0 53 4.5
Supplies 284 0.9 13 1.8 148 0.9 72 5.1 9 0.9 40 3.4
Vehicle operation and maintenance 413 1.3 22 3.2 218 1.3 23 1.6 0 0.0 11 1.0
Building operation and maintenance 254 0.8 5 0.7 130 0.8 26 1.8 0 0.0 13 1.1
Cleaning and Laundry 1269 3.9 1 0.2 635 3.8 46 3.2 2 0.2 24 2.0
Total recurrent costs 26470 81.1 308 44.4 13389 80.4 523 37.0 679 73.2 601 51.3
OPD Grand Total 32 622 693 16 657 1416 927 1171
Unit Cost
Number of annual visit 11 277 247 305 249
Cost per OPD visit 2.9 2.8 4.6 3.7
% proportion of Hospital\health centre
annual visit
98 % 2 % 55 % 45 %
Weighted unit cost per visit 2.8 0.1 2.89 2.6 1.7 4.2
% proportion of urban\rural
population
29 % 71 %
Urban/rural weighted cost per visit 0.8 3.0
Total weighted average cost per child treated 3.8
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US$ 218 per DALY averted. Other parameters with sub-
stantial influence on model results were transition prob-
abilities from well to moderate diarrhoea, diarrhoea case
fatality rate, effectiveness of ORS on moderate diarrhoea
treatment, transition probabilities from moderate to severe
diarrhoea, and the effectiveness of IV fluids on severe diar-
rhoea treatment and the discount rate for health outcomes.
Probabilistic sensitivity analysis
The probabilistic sensitivity analysis (Figure 3) reveals
the combined model uncertainty in cost and effective-
ness, and shows that for the rota vaccine alone strategy,
uncertainty is largely associated with effectiveness, while
uncertainty varies more equally between costs and ef-
fectiveness for the diarrhoea treatment alone and the
rotavirus vaccine plus diarrhoea treatment.
The cost effectiveness acceptability frontier (Figure 4) il-
lustrates that willingness to pay to avert a DALY decides
which intervention is likely to be most cost-effective. Untilwillingness to pay to avert a DALY exceeds US$ 40, the
null intervention is optimal. For willingness to pay for
health between US$ 40 and 80 the vaccine provided alone
has the highest probability of being optimal, while in the
range US$ 80 to 112 per DALY averted; diarrhoea treat-
ment alone is most likely to be cost-effective. When will-
ingness to pay exceeds US$ 112 per DALY averted the
combined strategy of providing both the vaccine and diar-
rhoea management is likely to be optimal.
Figure 4 also illustrates that there is a large degree of
uncertainty surrounding these findings, especially regard-
ing the ranges of willingness to pay for which the mono-
therapies may be considered optimal. In fact, both these
recommendations have less than 60% probability of being
cost effective. Uncertainty diminishes only when willing-
ness to pay exceeds about USD 160 per DALY, after which
the probability of the combined intervention being cost-
effective is higher than 80%. Rotavirus vaccine and diar-
rhoea treatment combined approaches a 100% probability
of being cost effective at a much lower level of willingness-
Table 4 Average inpatient cost for diarrhoea treatment, by location and level of service, 2012 US$
Cost category Urban Rural
Hospital % Health Centre Average % Hospital % Health Centre Average %
Capital Cost, N (%)
Buildings 3066 12.9 - 3066 12.9 277 10.1 - 277 10.1
Equipment 408 1.7 - 408 1.7 49 1.8 - 49 1.8
Vehicles 74 0.3 - 74 0.3 92 3.4 - 92 3.4
Training on diarrhoea management 679 2.9 - 679 2.9 285 10.4 - 285 10.4
Total capital costs 4227 17.8 - 4227 17.8 703 25.7 - 703 25.7
Recurrent Cost, N (%)
Personnel 15250 64.3 - 15250 64.3 1141 41.7 - 1141 41.7
Drugs and Medical supplies 1831 7.7 - 1831 7.7 163 5.9 - 163 5.9
Supplies 728 3.1 - 728 3.1 327 11.9 - 327 11.9
Vehicle operation and maintenance 30 0.1 - 30 0.1 98 3.6 - 98 3.6
Building operation and maintenance 550 2.3 - 550 2.3 111 4.1 - 111 4.1
Cleaning and Laundry 1111 4.7 - 1111 4.7 196 7.1 - 196 7.1
Total recurrent costs 19500 82.2 - 19500 82.2 2036 74.3 - 2036 74.3
IPD Grand Total 23727 23725 2739 2738
Unit cost
in-patient days 3103 3103 291 291
Cost per in-patient day 7.6 7.6 9.4 9.4
% proportion of urban\rural population 29 % 71 %
Urban/rural weighted cost in-patient day 2.2 6.7
Total weighted (urban/rural) average cost per in-patient day 8.9
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tic product (GDP) in 2011/2012, suggested by the World
Health Organisation as highly cost-effective [40].
Discussion
This is the first published cost-effectiveness analysis for
Tanzania comparing the potential benefit of rotavirus vac-
cine with diarrhoea management either in combination or
if each intervention were implemented separately. We
found that rotavirus vaccine provided as a package with
diarrhoea treatment is highly cost- effective compared to
the implementation of diarrhoea treatment alone or only
providing RV1 vaccine. The incremental cost effectiveness
ratio remained highly cost effective during sensitivity ana-
lysis. One way sensitivity analysis shows that for the most
influential parameter i.e. the effectiveness of rotavirusTable 5 Baseline cost effectiveness results
Strategy Cost Incremental co
Discounted
No Intervention 0.0 0.0
Rotavirus Vaccine Alone 59.3 59.3
Diarrhoea Management 112.2 52.9
Rotavirus V& Diarrhoea Management 166.7 54.5vaccine, the highest ICER is US$ 237 per DALY averted
which is lower than Tanzania’s GDP.
The Tanzanian package of essential health interven-
tions and the strategic plan for reduction of maternal
and child mortality (2008 to 2015), recommends giving
priority to interventions that are cost effective and ad-
dress the major causes of morbidity and mortality
[41,42]. Both policy documents recommend diarrhoea
treatment with ORS as a key intervention in diarrhoea
control. However, our study shows that diarrhoea treat-
ment alone is likely to be less cost effective than com-
bining it with rotavirus vaccination for reasonable levels
of willingness to pay per DALY averted. These findings
corroborate the current WHO recommendation on diar-
rhoea control, emphasising the provision of both pre-





Figure 2 Tornado diagram showing the uncertainty impact of individual parameters on the incremental cost effectiveness ratio. Black dotted line
represents the base case ICER. NB: The left hand presents the lower limit ICER values and the right hand upper limit of ICER.
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conditions, including epidemiology and capacity for ser-
vice provision may influence the finding that diarrhoea
treatment or vaccine provided alone is less cost effective,
but these are unlikely to change the main finding that
adding the vaccine is highly cost-effective.
At a unit cost between US$ 5.2 (urban health facilities)
to 9.4 in rural facilities per vaccine dose, estimated from
subsidised GAVI alliance prices[11] in additional to ad-
ministrative cost and vaccine wastage from primary cost
data. Our study shows that it costs twice as much to de-
liver the vaccine in the rural facilities as in the urban facil-
ities. This is primarily because there are fewer children in
the rural area accessing health care services. Hence there
are fewer patients to share the fixed capital costs and the
fixed personnel costs of each facility (Figure 2). In other
words, both vaccination and diarrhoea treatment are likely
to be more cost-effective in urban than in rural areas. Since
health services are generally better available and of higher
quality in urban areas, this means that scale up of rotavirusvaccination may represent an equity-efficiency trade-off.
Prioritizing urban areas will allow more children to be im-
munized when funds are insufficient for full coverage, but
at the same time this will further increase existing dispar-
ities. More empirical research is needed to explore the
distributive impacts of alternative policies, coupled with
deliberation and debate on the normative arguments.
The findings of our study are similar to previous studies
on a two-dose monovalent RV1 vaccine in other low-
income countries. A study from Malawi reported an ICER
value of US$ 75 per DALY averted at vaccine cost of US$
5.5 per dose [38]. Atherly et al. found a cost of US$ 78 per
DALY averted in the WHO AFRO region, at vaccine unit
cost of US$7 [37], and a study from India and Kenya also
reported that introduction of the monovalent rotavirus
vaccine would be highly cost effective [39,43], the unit cost
per vaccine in India study was US$7, in the Kenya study
the unit cost was between US$ 9.2 and US$ 7.4. However
none of these studies directly compared the benefit of
combining rotavirus vaccine with diarrhoea management,
Figure 3 Scatter plot of costs and health outcomes from probabilistic sensitivity analysis.
Figure 4 Cost effectiveness acceptability frontier showing the likelihood that any of the diarrhoea management strategy is cost effectiveness for
different levels of willingness to pay for health.
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the WHO-CHOICE project or other vaccination costing
studies.
Rotavirus vaccine is expected to provide further soci-
etal benefits not captured by our model [44], which only
includes the health provider perspective. Even if health
services for children in Tanzania are free, the out of
pocket expenditure for food, transport, and medicines
for diarrhoea are substantial and are estimated to be on
average US$ 5.5 per child admission [45]. In addition to
these direct costs, indirect costs associated with product-
ivity loss are likely to be highly relevant. Our model
therefore probably underestimates the full societal bene-
fits and, consequently, the cost-effectiveness of rotavirus
vaccination. The inclusion of RV5 as a comparator
might have enhanced the analysis and hence the results,
but we chose to exclude the intervention due to lack of
Tanzanian cost data.
Cost estimates for diarrhoea management and rolling
out the rotavirus vaccine were collected from only one
rural and one urban district. Our findings are therefore
not necessarily representative for districts that are differ-
ent in terms of income levels or other characteristics, or
for the whole country. Regional estimates could, how-
ever, be useful to inform national scale up. The unit
costs for diarrhoea treatment were collected in the ab-
sence of an immunization programme. After the rota-
virus vaccine roll out, the diarrhoea treatment costs
might change because of a possible reduction in the
number of OPD visits and IPD days. However, we can-
not predict that with certainty from our study. We had
no apriori evidence suggesting the degree of economies
of scale before vaccine introduction. The cost data may
be updated after roll-out to reflect possible impact of
vaccine on health care expenditure. Our model can eas-
ily be adapted using local and updated data to optimize
its local relevance.
The effectiveness data used in this work were retrieved
from various meta-analyses lacking direct head to head
comparisons between competing interventions. The lack
of network meta-analysis may impact on the precision of
our study results. Ideally network meta-analysis could
have been done to further synthesis the evidence, in-
crease precision of the model results and, hence minim-
ise the potential bias of using effectiveness data from
several different sources [46]. However these network
meta-analysis are only as good as the trials included in
them. In the setting in which this study was conducted,
these methods are not well developed and it was beyond
the scope of this analysis to perform an independent net-
work meta-analysis. Nevertheless, decisions in health care
resource allocation have to be made in this context, even
in the absence of precision data and more complex analyt-
ical and synthesis methods [47]. For further studies, werecommend inclusion of network meta-analysis. It would
also be useful if well-established bodies such as the Child
Health Epidemiology Reference Group (CHERG) and the
Cochrane collaboration consider extending the conven-
tional meta-analysis into network meta-analysis to generate
evidence for use in low-income settings.
Conclusions
A combination of rotavirus immunisation and diarrhoea
management for Tanzania is likely to be cost-effective
when willingness to pay for health exceeds US$ 112 per
DALY. Provisions of RV1 vaccine alone or diarrhoea
management alone are both less cost effectiveness alter-
natives. The roll out of the Rotavirus vaccine as a pack-
age with diarrhoea treatment will strengthen the efforts
to achieve the child health Millennium Development
Goals in Tanzania and should be seen as a high priority
intervention for child health improvement.
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